Europe — EMA
Granisetron Beta
Granisetron Beta is an oral 5-HT3 antagonist used to prevent chemotherapy and postoperative nausea and vomiting in the EU market.
Request sourcing
What is Granisetron?
Granisetron Beta is a prescription medication that contains the active ingredient granisetron. It is supplied as an oral product, though specific dosage form and strength are not disclosed. Classified as a 5-HT3 receptor antagonist, it belongs to the antiemetic therapeutic class and is marketed within the European Union.
What is Granisetron used for?
Granisetron Beta is indicated for the prevention of nausea and vomiting associated with specific medical procedures and treatments. It is commonly used in clinical practice for the following purposes:
- Prevention of chemotherapy‑induced nausea and vomiting (CINV) - Prevention of postoperative nausea and vomiting (PONV) - Management of nausea related to radiation therapy - Adjunct therapy for patients at high risk of emesis during surgical procedures - Supportive care in patients receiving highly emetogenic chemotherapy regimens
What are the side effects of Granisetron?
Granisetron Beta may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.
Common: - Headache - Constipation - Diarrhea - Fatigue - Dizziness - Flushing
Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias - Prolonged QT interval - Severe hypotension - Serotonin syndrome (when combined with other serotonergic agents)
What precautions apply to Granisetron?
Before starting Granisetron Beta, certain precautions should be considered to ensure safe use. Patients and healthcare providers should be aware of the following:
- Assess cardiac history, especially for QT prolongation risk - Review any known hypersensitivity to granisetron or similar compounds - Use cautiously in patients with electrolyte imbalances (e.g., low potassium or magnesium) - Monitor for signs of severe constipation or bowel obstruction - Consider renal or hepatic impairment when evaluating dosing needs - Discuss pregnancy and breastfeeding status with a healthcare professional, as safety data are limited
What does Granisetron interact with?
Granisetron Beta can interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects.
Avoid: - Other 5‑HT3 antagonists (duplicate therapy) - Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics) - Strong CYP3A4 inhibitors that may increase granisetron levels
Use with caution: - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol) due to serotonin syndrome risk - Medications that affect electrolyte balance (e.g., diuretics) - Anticholinergic drugs that may exacerbate constipation - Anesthetic agents used during surgery, as they may influence nausea control
